Nervous system

New Sleep Technology Provides Real-Time Sleep Stage Enhancement

Retrieved on: 
Wednesday, April 3, 2024
Automation, REM, Real-time, Nervous system, Health, Sleep, Research, Software, Code, Breathe, Pharmaceutical industry

MINNEAPOLIS, April 3, 2024 /PRNewswire/ -- Soltec Health, a pioneer in sleep and stress innovation, has developed a proprietary technology that supports certain nervous system functions to improve sleep. The Soltec Health System® delivers real-time, sleep stage-specific magnetic frequencies as needed for improved sleep, including restorative deep Delta sleep.

Key Points: 
  • The Soltec Health System® delivers real-time, sleep stage-specific magnetic frequencies as needed for improved sleep, including restorative deep Delta sleep.
  • The Z•TRACK wearable measures multiple sleep biometrics continuously to determine your current sleep stage and detect transitions to the next stage of sleep (REM, Deep, or Light sleep).
  • Everyone has a unique sleep stage cycle, and the System can detect sleep stage transitions as they occur.
  • When your sleep stage begins to change, the wearable transmits instructions to Z•GEN (the therapeutic device of the System) to emit sleep stage-specific magnetic frequencies that support the newly active sleep stage.

Insights into the Future of Neurology Devices: Exploring the Global Market Report by BCC Research

Retrieved on: 
Thursday, March 28, 2024
Epilepsy, Organization, MRI, Prevalence, Brain, Multiple sclerosis, Data analysis, Neuro, Alzheimer's disease, Nervous system, Patient, Radiosurgery, Research, Spinal cord stimulator, Electrode, Parkinson's disease, Low back pain, Investment, DSM-IV codes, Neurosurgery, Population growth, Ageing, Medical imaging

BOSTON, March 28, 2024 /PRNewswire/ -- According to the latest research study, the demand for Neurology Devices: Global Markets expected to grow from $23.7 billion in 2023 to $31.7 billion by the end of 2028 at a compound annual growth rate (CAGR) of  6.0% from 2023 through 2028.

Key Points: 
  • Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions.
  • The report looks at things like how much these devices are used, where they're used, and how the market for them is growing.
  • This report thoroughly examines the global market for neurology devices, categorizing it by product type and region.
  • Non-surgeons are increasingly performing spinal cord stimulation procedures instead of neurosurgeons due to the rising global burden of low back pain.

VAXA Launches ACTION Impact Nutrition, a revolutionary program to bridge malnutrition through food fortification

Retrieved on: 
Wednesday, March 20, 2024
Dicarboxylic acid, Nervous system, IUS, Brain, Vitamin, Nutrient, Malnutrition, ACTION, Iron

REYKJAVÍK, Iceland, March 20, 2024 /PRNewswire/ -- VAXA Technologies is proud to launch the ACTION Impact Nutrition Program that can bridge the malnutrition gap for millions of people in need, supported by responsible businesses with effective decarbonization strategies.

Key Points: 
  • REYKJAVÍK, Iceland, March 20, 2024 /PRNewswire/ -- VAXA Technologies is proud to launch the ACTION Impact Nutrition Program that can bridge the malnutrition gap for millions of people in need, supported by responsible businesses with effective decarbonization strategies.
  • Take ACTION with VAXA Technologies: https://vaxaimpact.com/take-action-with-vaxa/ .
  • The ACTION program is designed to provide improved nourishment for marginalized communities by fortifying traditional foods lacking in sufficient vitamins and nutrients with the VAXA Icelandic Ultra Spirulina (IUS) mix, a vegan natural ingredient rich in iron, protein, amino acids, and active natural B12, essential to nourish the brain and nervous system.

FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy

Retrieved on: 
Monday, March 18, 2024
Encephalitis, Locomotion, Brain, B cell, Bone marrow, Cell, Dietary supplement, Nervous system, Risk, Patient, Public, Urinary tract infection, Animal, Metachromasia, DSM-IV codes, Peripheral nervous system, Viral, Human services, Hope, Death, Quality of life, Atidarsagene autotemcel, Rash, Therapy, Metachromatic leukodystrophy, Natural history, Fever, MLD, Heated tobacco product, Safety, Disability studies, Cosmetics, Health, Vaccine, Food, Swelling, FDA, Liver, Multimedia, ARSA, Pharmaceutical industry

Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system.

Key Points: 
  • Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system.
  • The stem cells are collected from the patient and modified by adding a functional copy of the ARSA gene.
  • In children with MLD, treatment with Lenmeldy significantly reduced the risk of severe motor impairment or death compared with untreated children.
  • Eighty five percent of the children treated had normal language and performance IQ scores, which has not been reported in untreated children.

Akamai and Neural Magic Partner to Accelerate Deep Learning AI

Retrieved on: 
Tuesday, March 12, 2024
Cloud, Organization, Nervous system, GPU, AKAM, Partnership, MIT, SVP, Artificial intelligence, Running, AI, Software, Specialization, Deep learning, Cloud computing, CPU, Magic, Video game

CAMBRIDGE, Mass., March 12, 2024 /PRNewswire/ -- Akamai Technologies (NASDAQ: AKAM), the cloud company that powers and protects life online, and Neural Magic, a developer of software that accelerates artificial intelligence (AI) workloads, today announced a strategic partnership intended to supercharge deep learning capabilities on Akamai's distributed computing infrastructure. The combined solution gives enterprises a high-performing platform to run deep learning AI software efficiently on CPU-based servers. As an Akamai Qualified Computing Partner, Neural Magic's software will be made available alongside the products and services that power the world's most distributed platform for cloud computing, security, and content delivery.

Key Points: 
  • The combined solution gives enterprises a high-performing platform to run deep learning AI software efficiently on CPU-based servers.
  • Neural Magic's solution enables deep learning models to run on cost-efficient CPU-based servers rather than on expensive GPU resources.
  • "Scaling Neural Magic's unique capabilities to run deep learning inference models across Akamai gives organizations access to much-needed cost efficiencies and higher performance as they move swiftly to adopt AI applications."
  • Akamai and Neural Magic share a common origin, both having been born out of Massachusetts Institute of Technology (MIT).

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Wednesday, March 6, 2024
Nervous system, POC, AMIX, Collateral damage, Quality of life, Pain, Patient, Clinical trial, Disease, Pancreatic cancer, Ethanol, Medical imaging

THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has commenced patient enrollment for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We are pleased to commence enrollment of the PoC human clinical trial and take another step toward validating our clinical and regulatory plans for our technology,” commented Lori Bisson, Chief Executive Officer of Autonomix.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.
  • Confirmation of suitability will be affirmed by the primary oncology service caring for the patients.
  • Up to 5 additional patients will be included and treated according to protocol to ensure the physician’s familiarity with the procedure.

Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

Retrieved on: 
Tuesday, March 5, 2024
Skin cancer, EPP, Pigment, Nervous system, Attacca Quartet, Growth, XP, Skin, Xeroderma pigmentosum, Global health, Life, Parker, Risk, Health, Vitiligo, Peptide, Melanocortin, Patient, Medicine, Knowledge, Research, Brain, Pharmaceutical industry

The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.

Key Points: 
  • The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.
  • Philanthropy is central to the work of Lady Gaga and Michael Polansky, Sean Parker and Alexandra Parker.
  • At the event in Malibu, CLINUVEL announced the Photomedicine Foundation, which will count Mr Polansky as a trustee.
  • CLINUVEL is grateful to have their support as we translate our pharmaceutical technology into PhotoCosmetics and give back to underserved communities.

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Retrieved on: 
Tuesday, March 5, 2024
Nervous system, Science Advances, Immunotherapy, Spacecraft, Manuscript, ADC, Bi-specific T-cell engager, AGM, Patient, FLRT3, Cancer, Vaccine

The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.

Key Points: 
  • The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.
  • These data demonstrate that cancer cells can exploit AGM protein-protein interactions to evade T cell anti-tumor immunity by acting as checkpoint inhibitors to suppress T cell responses and immune function.
  • Future studies will dissect the roles of membrane and soluble FLRT3 on T cell signaling through UNC5B, and downstream pathways.
  • The data were generated in collaboration with Dr. David Langenau at the Massachusetts General Hospital Research Institute’s Molecular Pathology and Cancer Center.

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Retrieved on: 
Thursday, February 29, 2024
Nervous system, MEDLINE, POC, AMIX, Collateral damage, Pain, ChromeOS, Patient, Clinical trial, SIV, Disease, Naval ship, Ethanol, Medical imaging

THE WOODLANDS, TX, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a clinical site agreement with “АКFА MEDLINE" Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • Additionally, Autonomix announced the selection of Clinical Accelerator and Qmed, full service Clinical Research Organizations (CROs) specializing in medical devices to support the PoC human clinical trial.
  • Clinical Accelerator will be responsible for managing the clinical operations in country, including recruiting patients, SIV work, and patient treatment records and Qmed will be responsible for managing protocol and trial reporting, as well as managing patient data.
  • Lori Bisson, Chief Executive Officer of Autonomix commented, “We are pleased to execute these important agreements and final steps towards commencing patient enrollment in our first PoC human clinical trial.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

Retrieved on: 
Friday, February 23, 2024
Virtual, Nervous system, AMIX, Management

THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor Lunch Break: The Autonomix Opportunity event on Thursday, February 29, 2024 at 12:00 PM ET.

Key Points: 
  • Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29th at 12:00 PM ET
    THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor Lunch Break: The Autonomix Opportunity event on Thursday, February 29, 2024 at 12:00 PM ET.
  • As part of the event, Lori Bisson, Chief Executive Officer of Autonomix, will provide a corporate overview, business outlook, and discuss the Autonomix opportunity.
  • A live video webcast of the event will be available on the Events page under the Investors section of the Company’s website ( autonomix.com ).
  • A webcast replay will be available two hours following the live event and will be accessible for 90 days.